Objective: Early graft failure (EGF) is a major risk for death after heart transplantation. We studied the impact of an extra-corporeal membrane oxygenation (ECMO) temporary support on the operative mortality and the mean-term survival after EGF. Materials and methods: Between January 2000 and December 2006, 394 patients underwent orthotopic heart transplantation at our institution. EGF was observed in 90 (23%) patients. Fifty-four patients (14%) were treated with ECMO support, eight (2%) with other assisting devices, and 28 (7%) received maximal inotropic drug support only. Results: The overall mortality was 21% (83 patients). EGF was a major risk for death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p < 0001. Among patients supported with ECMO, 36 (67%) were weaned from the assisting device and 27 (50%) were discharged from the hospital. Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF improved long-term survival: 78% at 1 year and 70% at 5 years without EGF versus 37% at 1 year and 35% at 5 years with EGF. Patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF: 94% at 3 years. Conclusions: ECMO support is a reliable therapeutic option in severe EGF after cardiac transplantation; furthermore, patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF. #
Introduction
Early graft failure (EGF) represents the most common cause of in-hospital mortality after cardiac transplantation [1] with a negative impact on early and long-term survival [2] . Despite its high mortality, the treatment of EGF is not yet well established. Therapeutic options for EGF usually include a high dose of inotropes and may also require mechanical circulatory support, even if this may be associated with an extremely high operative mortality [3] [4] [5] Emergency retransplantation in the setting of EGF has been attempted in the past [6, 7] , but it carried an unacceptable operative mortality and therefore has been abandoned. Extra-corporeal membrane oxygenation (ECMO), a well-established technique for the treatment of post-cardiotomy shock [8, 9] , has been recently used as a therapeutic option for EGF [10] [11] [12] . The ECMO programme was initiated in 2001; and we report here our experience of using ECMO in the setting of EGF.
Materials and methods

Patients
Between January 2000 and December 2006, 394 patients underwent cardiac transplantation in our institution. Until July 2004, recipient data were obtained from patients' charts. After July 2004, a digital database system was introduced at our institution (DxCare, Medasys Corporation) and it was used as the source of data for all patients. Donor data as well recipient allocation were obtained from Cristal, the database of the French regulatory agency of transplantation, the Agence of Biomedecine. To further analyse the occurrence of EGF over the years, the study group was divided in two eras: in era 1, 150 patients underwent transplantation between 2000 and June 2003; in era 2, 244 patients had undergone transplantation between July 2003 and 2006. The year 2003 represented a transitional year during which we faced an increased mortality on the waiting list and we tried to expand the criteria for donors acceptance in order to bridge the gap between organ supply and demand. Moreover, a national high emergency waiting list was opened in July 2004.
Definitions and outcomes
Primary outcomes were occurrence of EGF, in-hospital mortality and late survival. EGF was defined as the need of inotrope support with epinephrine >0.3 mg kg À1 min À1 and/ or the need of mechanical circulatory support in the immediate postoperative 48 h. Operative mortality was defined as death of the patient before the 30th postoperative day (POD) or death of the patient at any POD, if never discharged from the hospital.
Organ preservation and surgical technique
The preservation solution consisted of Celsior solution. After retrieval, hearts were transported immersed in hypothermic Ringer's lactate solution. At the time of implantation, white-cell unfiltered cold blood cardioplegia was infused into the aortic root to aid in myocardial protection and removal of air. Bicaval anastomosis was used for the right atrium according to the surgeon's preference. Patients were weaned from cardio-pulmonary bypass according to the following protocol:
-Low-dose inotrope support with isoprenaline and norepinephrine was started during completion of the anastomosis before aortic clamp removal. Nitric monoxide was added to protect the right ventricle from overload. Patients were sequentially paced if necessary. -After aortic clamp removal, the reperfusion time was directly proportional to the ischaemic time: during this period, the heart was allowed to recover while completely unloaded. If needed, norepinephrine was replaced by epinephrine. -Weaning from cardiopulmonary bypass (CPB) was achieved with gentle, progressive filling of the heart, while carefully monitoring the central venous pressure and avoiding dilation of right ventricle. If the latter occurred, CPB was promptly resumed at full flow and the inotrope dose was increased. -Institution of a mechanical circulatory support was indicated in case of inability to wean from CPB despite an adequate reperfusion time and high-dose inotrope support.
ECMO characteristics and technique
The extra-corporeal system consisted of polyvinyl chloride tubing, a membrane oxygenator (Quadrox Bioline, JostraMaquet, Orléans, France), a centrifugal pump (Rotaflow, Jostra-Maquet, Orléans, France) and either percutaneous arterial and venous femoral or central right atrial and aortic cannulae (Biomedicus Carmeda, Medtronic, Boulogne-Billancourt, France). An oxygen/air blender (Sechrist Industries, Anaheim, CA, USA) was used to ventilate the membrane oxygenator. When percutaneous femoral ECMO was instituted, an additional 5-Fr cannula was inserted distally into the femoral artery to prevent possible leg ischaemia.
Patients were anticoagulated with heparin to achieve an activated cephalin time (TCA) of twice the control. During the initial procedures, peripheral cannulation was preferred to facilitate removal. However, in the more recent operations, intra-thoracic implantation was more commonly used to avoid lower limb ischaemic complication and achieve a better outflow.
Weaning protocol
When a pulsatile arterial waveform was maintained for at least 24 h and the echocardiographic evaluation demonstrated systolic heart function recovery and pulmonary blood oxygenation was not compromised, an ECMO-weaning trial was undertaken by progressively reducing pump flow to <1 l min À1 (respecting the minimum rotational speed of 1500 rpm to prevent retrograde flow). This achieved, the arterial and venous lines were clamped for 1-2 min (after increasing the anticoagulation drug). In this setting, if the LV ejection fraction was >35-40%, aortic blood flow timevelocity integral was >10 cm and cardiac index was >2.2 l min m À2 , then the flow was maintained at between 1.5 and 2 l/min for 24 h. If under these conditions the patient's haemodynamic status remained stable, the ECMO was removed and the mediastinum or femoral access surgically repaired. Epinephrine was routinely used during weaning.
Statistical analysis
Univariate analysis was performed using chi-square tests for categorical variables and unpaired Student's t or MannWhitney tests for continuous variables. Kaplan-Meier method was used for survival analysis. All statistical analyses were performed with SAS V8 statistical package.
Results
Preoperative recipient and donor characteristics
Preoperative recipient and donor characteristics are presented in Table 1 . The comparison between eras 1 and 2 shows that recipients in era 2 were more often diabetic (14% vs 6%, p = 0.01), they waited a longer time before being transplanted (189 AE 335 days vs 114 AE 200 days, p = 0.005), were more often under ECMO preoperatively (6% vs 0%, p = 0.002), more often ventilated (7% vs 2%, p = 0.04) or inotrope dependent (20% vs 11%, p = 0.01). Donors of era 2 were significantly older (47 AE 13 years vs 42 AE 13 years, p = 0.001), were more often diabetic (6% vs 1%, p = 0.03) and ischaemic times were significantly longer (167 AE 57 min vs 151 AE 61 min, p = 0.01).
Immediate postoperative results
Operative data and immediate postoperative results are summarised in Table 2 .
There were 83 (21%) in-hospital deaths. EGF occurred in 90 (23%) patients. Twenty-eight patients (7%) were treated by high-dose inotrope support alone, while 62 (16%) were supported by mechanical circulatory support (MCS): ventricular assist device (VAD, Thoratec, n = 2), right ventricular assist device (Biomedicus Centrifugal Pump, n = 6), ECMO (n = 54; peripheral, group P, n = 28; central, group C, n = 26). EGF was a major risk of death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p < 0.001.
Occurrence of EGF increased over the years, being significantly more frequent in era 2 than in era 1 (27% vs 17%, p = 0.02, Table 2 ). In addition, the mortality was higher in era 2 than in era 1, but this increase did not reach a statistical significance (24% in era 2 vs 17% in era 1, p = 0.09). Treatment of EGF by high dose inotropic support was 8% in era 1 versus 4% in era 2, but this difference was not statistically significant; on the other hand, eight patients (6%) in era 1 were supported with MCS other than ECMO versus no patient in era 2; and only three patients (2%) in era 1 underwent ECMO support versus 51 patients (21%) in era 2 ( p < 0.001, Table 2 ).
Patients without EGF
The mortality rate of patients who did not experience EGF was 13% (35 patients). Causes of death were infection (n = 26), cerebro-vascular accident (CVA) (n = 4), respiratory (n = 3) and rejection (n = 2).
Patients with EGF treated by high-dose inotrope
Among the 28 patients treated with inotropes, 15 patients died (54%). The causes of death were infection (n = 8), lowoutput cardiac syndrome (n = 5) and rejection (n = 2).
Patients with EGF treated by mechanical circulatory support other than ECMO
Both patients supported with VAD died; the first patient died soon after VAD implantation because of a low-output cardiac syndrome. The other patient was weaned from VAD after 78 days, but died of a cerebro-vascular accident. Among the six patients supported with RVAD, two patients were discharged, whereas four died while on support. The causes of death were refractory pulmonary hypertension (n = 2), infection (n = 1) and low-output cardiac syndrome.
Patients with EGF treated by ECMO
Among the 54 patients supported with ECMO, 36 were weaned from the assistance and 27 were discharged. Details of support and results according to the type of cannulation are presented in Table 3 . Delay of implantation was significantly different according to the type of cannulation. Seventeen patients of group P (61%) versus 24 patients (92%) of group C were supported before ICU admission. On the other hand, 11 patients of group P (39%) versus two patients (8%) of group C underwent ECMO support after the ICU admission ( p = 0.007).
Both groups showed similar duration of support (7 AE 3 days in group P vs 6 AE 4 days in group C), weaning rates (68%, 19 patients, in group P vs 65%, 17 patients in group C) and survival (50%, 14 patients, in group P vs 50%, 13 patients in group C). Morbidity was similar between the two groups, except the occurrence of vascular complications at the cannulation site in group P (5 patients, 18%). The causes of death in group P while on support were low-output cardiac syndrome (n = 2), CVA (n = 1), septic shock (n = 1), postoperative bleeding (n = 1) and refractory vasoplegia (n = 2). The causes of death in group P after weaning were low-output cardiac syndrome (n = 1), CVA (n = 1), septic shock (n = 2) and hypoxic arrest during tracheotomy weaning (n = 1). Two patients of group P died of CVA and septic shock after being bridged to total artificial heart (TAH, CardioWest, SynCardia, Tucson, AZ, USA). The causes of death in group C while on support were CVA (n = 2), septic shock (n = 1), postoperative bleeding (n = 4), gastro-intestinal bleeding (n = 1) and refractory vasoplegia (n = 1). The causes of death in group C after weaning were septic shock (n = 2), iatrogenic haemothorax (n = 1) and hypoxic arrest during tracheotomy weaning (n = 1).
Late results
Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF was correlated with a better long-term survival: 78% at 1 year and 70% at 5 years without EGF versus 37% at 1 year and 35% at 5 years with EGF (Fig. 1a, p < 0.001 ). Patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF: 94% at 3 years (Fig. 1b) . Table 3 Morbidity and mortality of ECMO patients.
All
Group 
Discussion
Occurrence of EGF
As stated by the 2007 International Society for Heart and Lung Transplantation (ISHLT) report [1] , EGF is a major cause of death in the perioperative period after cardiac transplantation. Its incidence ranged between 4% and 24% [2, 4, 13, 14] , according to whether the definition of EGF was conservatively based on the need for mechanical support or if it also included patients requiring high-dose inotropic support. Despite its high mortality, the mechanisms underlying EGF are still barely understood and the risk factors which may predict this complication have not been characterised yet. Theoretically, many factors could interact in the genesis of EGF: increased pulmonary vascular resistances, preservation injury or even intrinsic organ donor dysfunction. The following risk factors have been identified: ischaemic time [2, 4, 12, 14] , donor age [4, 14] and pre-transplant VAD [2] . The incidence of EGF in our series increased over the years: this trend could be explained by the interaction between the evolving recipient and donor profiles. The recipients in era 2 were more often diabetic, inotrope and ventilator dependent, and the bridge to transplant was achieved more frequently by ECMO than VAD. The significantly higher rate of patients on inotropes and lower rate of patients on VAD in era 2 could be explained by the opening of a national highemergency waiting list in July 2004, resulting in a highest priority on the waiting list for selected patients. Hearts available for this probably sicker population were retrieved from older donors, with longer ischaemic times. Marasco and colleagues reported a 43% increased risk of graft failure for every hour of ischaemic time after the fourth hour [14] . Donor age is a well-established risk factor for early and late mortality after cardiac transplantation: [1, 17] mean donor age in our series was higher than in the ISHLT data [1] and the other reports [2, 4, [14] [15] [16] [17] . Furthermore, 43% of donors of 50 years and older (Table 1) is greater by far than the 8-10% currently reported [15] [16] [17] .
ECMO support for EGF
As EGF physiopathology is poorly understood, the treatment also remains unclear. Re-transplantation early after EGF carries an unacceptable mortality. Until recent years, MCS with VAD was the only available option for EGF, but it was also associated with a high mortality: our discharge rate is similar to those reported by other groups [3, 4, 11, 14] . Motivated by the improving results of ECMO support for adult post-cardiotomy shock [8, 9] and encouraged by other preliminary reports [10, 12] , we started using ECMO to temporarily support patients with EGF after cardiac transplantation. In our experience, recovery of grafts occurred after a mean of 7 AE 3 days, with a weaning and survival rates of respectively 68% and 50% (Table 3) , similar to those published by Taghavi (weaning 77%, survival 54%) [11] , and Chou (weaning 84%, survival 53%) [12] . These encouraging results could be explained by the fact that ECMO provides a full circulatory support with minimal surgical trauma, avoiding end-organ damage and allowing both ventricles to rest and recover. The leading causes of death were surgical bleeding, CVA and septic shock. It is important to remember that these patients remain very fragile, even after weaning; they need aggressive antibiotic therapy and the nursing staff must be very attentive: two patients died of hypoxic arrest after tracheotomy weaning.
Treatment of EGF has evolved over the years: in era 1, patients were treated by high-dose inotrope support or by MCS with VAD. In era 2, the majority of patients were supported by ECMO. This ongoing process, underlined also by Taghavi, may result in a more aggressive policy of accepting marginal donors, with a lower threshold for ECMO support in these patients: in their population, they report only 15 cases of right ventricular failure refractory to drug therapy between 1984 and 2000 versus 13 cases between 2000 and 2003 [11] . Indeed, an increased risk of EGF must always be weighted against the probability of death on the waiting list. Furthermore, as shown in Fig. 1b , EGF seems not to have a consequence on the mid-term graft function: the 1-year conditional survival at 3 years of patients having experienced EGF is similar to the other transplanted patients, the burden of the higher mortality associated with EGF being limited to the perioperative period.
ECMO support: peripheral versus central cannulation
ECMO support can be deployed with peripheral or central cannulation. In our series, outcomes were not dependent on the type of cannulation, excepting the occurrence of vascular complications of the femoral artery in group P. At the beginning of our experience, we used the peripheral approach with cannulation of the femoral vein and artery, as described by Taghavi et al. [10] . Such a technique is minimally invasive and quickly available even at the bedside; removal of the ECMO is performed without re-opening the chest, which could reduce the risk of infection. Furthermore, our initial attitude was less aggressive, with a higher threshold for ECMO support. The decision for implantation was taken later, sometimes after the return to ICU and in an emergency context: in such cases the bedside implantation of a femoral ECMO was the easiest solution. As shown in Table 3 , although the mean delay between the end of the transplantation and the implantation of the ECMO is not significantly longer in group P than in group C, femoral cannulation was the preferred option after admission to ICU: 11 patients (39%) of group P versus two patients (8%) of group C were supported after admission in ICU ( p = 0.007).
Despite the easier management of the peripheral ECMO, our attitude changed over the years for the following reasons:
-The femoral approach was associated with vascular complications of the cannulation site in five patients, even if we did not experience any late complication of the femoral cannulation, as reported by Zimpfer [18] . -In some patients, the femoral cannulation could not provide a satisfactory circulatory support, probably because of an insufficient venous drainage or a relatively small diameter of the arterial cannula: two patients in group P died of cardiogenic shock despite the institution of circulatory support.
-Surprisingly, the use of central cannulation was not associated with an increased risk of infections or mediastinitis.
Therefore, as reported by Marasco et al. [14] , our actual policy is ECMO support with central cannulation, unless if the patient is on a femoral ECMO preoperatively or if the implantation is performed in the ICU on an emergency basis.
Limits
As stated in the Section 2, this retrospective study carries all the limits that a non-randomised design imposes.
Firstly, any comparison between ECMO with VAD for circulatory support after cardiac graft failure was not reliable, because of the small number of VAD patients, treated with different types of devices.
Secondly, apart from the impossibility of coming off CPB, the decision for ECMO support was taken according to haemodynamic, echographic and biochemical parameters, which were not available for a further analysis. Moreover, the threshold for support evolved with time, with a trend towards an earlier ECMO implantation.
Thirdly, the comparison between the two historical eras was not randomised nor was it the aim of the article: we investigated why the incidence of EGF increased over the years. As for the historic analysis, the comparison between the two types of cannulation was also not randomised. In view of all the reasons stated in the discussion section, we do not believe that such randomisation could be even desirable.
Conclusions
Despite the limits of its retrospective design, this study represents the largest series of ECMO circulatory support for EGF and it confirms that ECMO is a reliable therapeutic option for treatment of severe graft failure after cardiac transplantation.
Moreover, late mortality seems not to be affected by posttransplant ECMO: after the first year, EGF patients have the same life expectancy at 3 years as the other transplanted patients. Further studies will be needed to establish the correct threshold for ECMO support and to provide long-term results.
Appendix A. Conference discussion Dr H. Reichenspurner (Hamburg, Germany): Could you comment maybe on the issue of doing an additional left atrial cannulation? We did that in a number of ECMO patients because we found that otherwise sometimes you can get some severe pulmonary congestion if you don't also drain the left side of the heart. Dr D'Alessandro: We recently adopted left heart drainage in ECMO patients, to avoid pulmonary congestion. However, in this series of patients transplanted between 2000 and 2006, no patient had left heart drainage.
Dr Reichenspurner: And didn't you state a 67% recovery, but only 50% made it at the end?
Dr D'Alessandro: Indeed, these patients remain very fragile even after recovery, with a very high rate of infectious complications: eight patients died after weaning off from circulatory support, mostly because of septic shock or respiratory complications.
Dr Reichenspurner: And regarding your experience with the LVAD, that is something one would need to discuss a little bit. Because in our experience, we have really had much better success using biventricular support with a BiVAD system rather than ECMO because I think you can close the chest. The risk of infection is much lower.
Dr Y. Toyoda (Pittsburgh, Pennsylvania): I think the most common primary graft failure is isolated right ventricular failure, do you agree with that, or biventricular failure in this series? What was the most common type?
Dr D'Alessandro: We did not look into the precise aetiology of the graft failure; however I agree with you that most of the patients experienced right ventricular failure.
Nevertheless, we support these patients with ECMO, without making any difference between isolated right or biventricular failure. Dr D'Alessandro: In fact, we experienced a higher mortality on the waiting list and so we moved towards a more aggressive policy of donors' acceptance: 45% of our donors were older than 50 years, a figure that is much higher than currently reported in the series with older donors, which is about 8%. On the other hand, our recipients are particularly sick, because frequently we receive them on an emergency status, and we are obliged to use an ECMO support as a bridge to transplantation.
Finally, it is difficult to answer this question because if you will be more aggressive in donor acceptance, you probably will have to face more graft failures. We just presented our results, and we only recommend ECMO support as an effective treatment after graft failure.
Dr Pavie: I want to do a brief comment. It is clear at this moment in La Pitie we have too many patients, nine on the waiting list. After that, and you pose it clearly for the procurement, in France we use some graft, and we don't use. We push probably too much at one moment. We change the whole of emergency, and you have seen that the right proportion of graft now can be used in high emergency.
It was good for two years, but probably we have in the close future exactly the same things that occur with heart transplant, and now you have a very big waiting time on emergency case.
And now we go back a little, and we try to find a middle position to reduce mortality on the waiting list and not doing this too much as deaths on transplantation. It's always the same thing in transplantation. It's a difficult job, but you know that.
